Barclays raised the firm’s price target on Neurocrine to $169 from $150 and keeps an Overweight rating on the shares. The analyst says the Q1 report sets up a catalyst filled 2024.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine backs FY24 INGREZZA net product sales view $2.1B-$2.2B
- Neurocrine reports Q1 adjusted EPS $1.20, consensus $1.01
- Neurocrine Biosciences Reports First Quarter 2024 Financial Results
- Neurocrine announces FDA approval of INGREZZA SPRINKLE capsules
- Neurocrine management to meet with Oppenheimer